Bimi International Medical Inc

NASDAQ BIMI

Download Data

Bimi International Medical Inc Working Capital To Sales Ratio 5 year CAGR for the Trailing 12 Months (TTM) ending September 30, 2023: -36.66%

Bimi International Medical Inc Working Capital To Sales Ratio 5 year CAGR is -36.66% for the Trailing 12 Months (TTM) ending September 30, 2023. The working capital to sales ratio measures the proportion of working capital to revenue. It is calculated by dividing the difference between current assets and current liabilities by revenue. This ratio provides insights into the efficiency of working capital utilization relative to revenue generation. A higher ratio suggests better utilization of working capital to generate sales revenue. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Bimi International Medical Inc Working Capital To Sales Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was -0.16, a -176.23% change year over year.
  • Bimi International Medical Inc Working Capital To Sales Ratio for the Trailing 12 Months (TTM) ending September 30, 2021 was 0.22, a 105.66% change year over year.
  • Bimi International Medical Inc Working Capital To Sales Ratio for the Trailing 12 Months (TTM) ending September 30, 2020 was -3.82, a 77.60% change year over year.
  • Bimi International Medical Inc Working Capital To Sales Ratio for the Trailing 12 Months (TTM) ending September 30, 2019 was -17.04, a -254.05% change year over year.
NASDAQ: BIMI

Bimi International Medical Inc

CEO Mr. Tiewei Song
IPO Date Oct. 18, 2006
Location China
Headquarters Chongqing Corporation Avenue, Chongqing, China, 400010
Employees 296
Sector Healthcare
Industry Pharmaceutical retailers
Description

BIMI Holdings Inc., together with its subsidiaries, engages in the retail and wholesale distribution of medical devices, and pharmaceutical and other healthcare products in the People's Republic of China. The company operates in four segments: Wholesale Pharmaceuticals, Wholesale Medical Devices, Medical Services, and Retail Pharmacies. It distributes Stryker spinal products, Olympus endoscopes, imported imaging products, and diagnostic imaging equipment to drug stores, private clinics, pharmaceutical dealers, and hospitals in the Southwest region of the People's Republic of China. The company also distributes varieties of products, including raw ingredients for pharmaceutical products, antibiotics, cardiovascular drugs, and anti-obesity medicines. In addition, it offers prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicines, personal and family care products, medical devices, and miscellaneous items under the Lijiantang Pharmacy brand name. Further, the company provides medical services in the hospitals, as well as IT research and development services; and operates two private hospitals in China. It sells its medicine and other healthcare products to customers through its directly owned stores. The company was formerly known as BIMI International Medical Inc. and changed its name to BIMI Holdings Inc. in January 2024. BIMI Holdings Inc. was incorporated in 2000 and is headquartered in New York, New York.

Similar companies

MDVL

Medavail Holdings Inc

NA

NA

PETS

PetMed Express Inc

NA

NA

LFLY

Leafly Holdings Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email